AffaMed Therapeutics Announces Approval for the Phase IIb Clinical Study of AM006 in China for the Treatment of Parkinson’s Disease
May.2021
AffaMed Therapeutics Announces Appointment of Vijay Karwal as Chief Financial Officer
Mar.2021
AffaMed Therapeutics and SIFI announce Joint Venture to serve Greater China Market
Mar.2021
Affamed Therapeutics announces completion of over US$170 million series B financing and appoints Dr. Ji Li as President and Board Member
2020
Oct.2020
AffaMed Therapeutics and Ocular Therapeutix announce license agreement and collaboration for DEXTENZA® and OTX-TIC in Asia
Oct.2020
AffaMed Therapeutics and EverInsight Therapeutics merged with Dayao Zhao, M.D., Ph.D. appointed as CEO
Jun.2020
EverInsight Therapeutics and VistaGen Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia
2019
Aug.2019
EverInsight Therapeutics established
Feb.2019
AffaMed Therapeutics partners with Samsung Bioepis to develop and commercialize biosimilars in China
